Mylan and Lupin have gained the necessary recommendation to begin marketing their etanercept biosimilar in Europe.
Nepexto, an etanercept biosimilar, has gained a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, recommending use of the product.
Nepexto has received a positive opinion for all indications of the reference product (Enbrel), including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and nonradiographic axial spondyloarthritis), plaque psoriasis, and pediatric plaque psoriasis, according to Mylan NV and Lupin Limited, which have partnered in the development of the biosimilar.
“This milestone brings us 1 step closer to bringing an affordable biosimilar to etanercept to the European market through our partner Mylan,” said Vinita Gupta, chief executive officer of Lupin, in a statement. The companies began collaborating in 2018 to bring an etanercept biosimilar to the European market.
Enbrel, marketed by Amgen and Wyeth Pharmaceuticals, had sales of roughly $9.6 billion globally in 2019, according to IQVIA. In the United S, the comparable revenue figure was $5 billion.
The EMU committee opinion was based on a bioequivalence assessment that included preclinical and clinical studies. In addition, a phase 3 clinical study in patients with moderate-to-severe active rheumatoid arthritis confirmed equivalence of Nepexto to the reference product in terms of efficacy, safety, and immunogenicity, the statement said.
There are 2 approved etanercept biosimilars in the US: Samsung Bioepis’ Eticovo and Sandoz’ Erelzi. However, neither has launched. Erelzi received FDA approval in 2016 and has been delayed by litigation. Eticovo was approved in 2019, and no launch date has been announced.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.